Ipilimumab is a human monoclonal antibody intended to be used as a drug to activate the immune system.
In response to the FDA’s decision, BMS has submitted further analysis of data pertaining to the current application for pre-treated advanced melanoma and the agency considers this to be a major amendment to the drug’s BLA.
BMS said that it looks forward to continuing its close collaboration with the FDA on this application.